Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Infectious | 23 | 2021 | 99 | 5.250 |
Why?
|
| HIV Infections | 43 | 2023 | 2207 | 3.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 12 | 2021 | 67 | 1.870 |
Why?
|
| Anti-HIV Agents | 15 | 2020 | 394 | 1.540 |
Why?
|
| Microcephaly | 3 | 2018 | 18 | 1.480 |
Why?
|
| Congenital Abnormalities | 2 | 2019 | 19 | 1.390 |
Why?
|
| Pregnancy | 29 | 2023 | 1503 | 1.250 |
Why?
|
| Puerto Rico | 17 | 2021 | 1352 | 1.050 |
Why?
|
| HIV-1 | 16 | 2019 | 678 | 1.020 |
Why?
|
| Pregnancy Outcome | 6 | 2019 | 90 | 0.980 |
Why?
|
| Ritonavir | 6 | 2020 | 14 | 0.870 |
Why?
|
| Cyclonic Storms | 3 | 2021 | 62 | 0.800 |
Why?
|
| Female | 54 | 2023 | 19873 | 0.800 |
Why?
|
| Syphilis | 1 | 2021 | 27 | 0.780 |
Why?
|
| Infant, Newborn | 13 | 2019 | 871 | 0.730 |
Why?
|
| Adaptation, Psychological | 3 | 2021 | 358 | 0.700 |
Why?
|
| Pregnancy Complications | 2 | 2019 | 132 | 0.690 |
Why?
|
| AIDS Vaccines | 5 | 2013 | 30 | 0.660 |
Why?
|
| Humans | 57 | 2023 | 34853 | 0.640 |
Why?
|
| Hospitals, University | 1 | 2017 | 38 | 0.630 |
Why?
|
| Adult | 34 | 2021 | 11034 | 0.590 |
Why?
|
| Brain | 3 | 2018 | 1268 | 0.590 |
Why?
|
| Social Support | 2 | 2017 | 356 | 0.590 |
Why?
|
| Disasters | 1 | 2017 | 64 | 0.580 |
Why?
|
| Health Policy | 2 | 2021 | 149 | 0.580 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2017 | 55 | 0.550 |
Why?
|
| Family | 1 | 2015 | 162 | 0.500 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2015 | 17 | 0.500 |
Why?
|
| Health Personnel | 1 | 2016 | 200 | 0.500 |
Why?
|
| Influenza Vaccines | 2 | 2015 | 50 | 0.470 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 292 | 0.470 |
Why?
|
| Caregivers | 1 | 2015 | 167 | 0.470 |
Why?
|
| Benzoxazines | 3 | 2020 | 46 | 0.460 |
Why?
|
| Public Health | 2 | 2018 | 348 | 0.460 |
Why?
|
| Prejudice | 2 | 2010 | 101 | 0.450 |
Why?
|
| Primary Prevention | 1 | 2012 | 57 | 0.430 |
Why?
|
| Quality of Life | 1 | 2015 | 459 | 0.410 |
Why?
|
| Young Adult | 13 | 2019 | 4012 | 0.400 |
Why?
|
| RNA, Viral | 10 | 2019 | 287 | 0.380 |
Why?
|
| Saquinavir | 2 | 2007 | 3 | 0.370 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 790 | 0.370 |
Why?
|
| Adolescent | 14 | 2019 | 5035 | 0.360 |
Why?
|
| HIV Protease Inhibitors | 2 | 2015 | 22 | 0.360 |
Why?
|
| Emotions | 1 | 2012 | 204 | 0.360 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 341 | 0.360 |
Why?
|
| Viral Load | 10 | 2019 | 300 | 0.350 |
Why?
|
| Male | 21 | 2019 | 18870 | 0.350 |
Why?
|
| Education, Public Health Professional | 1 | 2009 | 18 | 0.350 |
Why?
|
| HIV Fusion Inhibitors | 2 | 2008 | 4 | 0.340 |
Why?
|
| Cyclohexanes | 2 | 2008 | 29 | 0.340 |
Why?
|
| Health Services Research | 1 | 2009 | 133 | 0.330 |
Why?
|
| HIV Seropositivity | 3 | 2010 | 182 | 0.330 |
Why?
|
| Mentors | 1 | 2009 | 111 | 0.320 |
Why?
|
| Prospective Studies | 9 | 2023 | 1353 | 0.320 |
Why?
|
| Research Personnel | 1 | 2009 | 133 | 0.320 |
Why?
|
| Triazoles | 2 | 2008 | 85 | 0.320 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2007 | 2 | 0.310 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2007 | 38 | 0.290 |
Why?
|
| Neoplasms | 1 | 2016 | 1033 | 0.290 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2019 | 16 | 0.280 |
Why?
|
| Lymphocyte Subsets | 1 | 2015 | 19 | 0.270 |
Why?
|
| Infant | 5 | 2019 | 1014 | 0.260 |
Why?
|
| Cohort Studies | 8 | 2019 | 1422 | 0.260 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2011 | 214 | 0.260 |
Why?
|
| Education | 1 | 2005 | 48 | 0.260 |
Why?
|
| Influenza, Human | 1 | 2015 | 79 | 0.250 |
Why?
|
| Minority Groups | 1 | 2009 | 537 | 0.240 |
Why?
|
| Survivors | 1 | 2005 | 126 | 0.240 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2007 | 248 | 0.240 |
Why?
|
| Desogestrel | 2 | 2020 | 4 | 0.230 |
Why?
|
| Immune Tolerance | 1 | 2013 | 61 | 0.220 |
Why?
|
| Health Status Disparities | 1 | 2009 | 583 | 0.220 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 57 | 0.220 |
Why?
|
| HIV Antigens | 2 | 2008 | 5 | 0.220 |
Why?
|
| CD4 Lymphocyte Count | 7 | 2010 | 185 | 0.210 |
Why?
|
| Middle Aged | 15 | 2020 | 9642 | 0.200 |
Why?
|
| Antibodies, Viral | 2 | 2019 | 252 | 0.200 |
Why?
|
| Contraceptive Agents, Female | 1 | 2020 | 23 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 2561 | 0.180 |
Why?
|
| Lynestrenol | 1 | 2019 | 1 | 0.180 |
Why?
|
| Nicaragua | 1 | 2019 | 3 | 0.180 |
Why?
|
| Guatemala | 1 | 2019 | 17 | 0.180 |
Why?
|
| Colombia | 1 | 2019 | 19 | 0.180 |
Why?
|
| Contraceptive Agents | 1 | 2019 | 13 | 0.180 |
Why?
|
| Peru | 1 | 2019 | 26 | 0.180 |
Why?
|
| Premature Birth | 2 | 2019 | 71 | 0.180 |
Why?
|
| Language Development | 1 | 2019 | 18 | 0.180 |
Why?
|
| Pregnancy Trimester, First | 1 | 2019 | 24 | 0.180 |
Why?
|
| Brazil | 1 | 2019 | 66 | 0.180 |
Why?
|
| Drug Therapy, Combination | 4 | 2010 | 217 | 0.180 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 81 | 0.180 |
Why?
|
| Eye Abnormalities | 1 | 2018 | 6 | 0.170 |
Why?
|
| Fetal Growth Retardation | 1 | 2019 | 51 | 0.170 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2018 | 39 | 0.170 |
Why?
|
| Attitude to Health | 3 | 2013 | 311 | 0.170 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 57 | 0.170 |
Why?
|
| Child Development | 1 | 2019 | 84 | 0.170 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2023 | 33 | 0.160 |
Why?
|
| Qualitative Research | 2 | 2021 | 393 | 0.160 |
Why?
|
| Gels | 4 | 2019 | 41 | 0.160 |
Why?
|
| Relief Work | 1 | 2017 | 7 | 0.160 |
Why?
|
| Antiviral Agents | 2 | 2017 | 148 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2018 | 288 | 0.160 |
Why?
|
| Calcinosis | 1 | 2017 | 56 | 0.150 |
Why?
|
| HIV | 3 | 2007 | 97 | 0.150 |
Why?
|
| Obstetrics | 1 | 2017 | 38 | 0.150 |
Why?
|
| Rectum | 1 | 2017 | 22 | 0.150 |
Why?
|
| Pyridazines | 1 | 2016 | 14 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2017 | 1349 | 0.150 |
Why?
|
| Double-Blind Method | 4 | 2011 | 269 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 3 | 2015 | 139 | 0.140 |
Why?
|
| Love | 1 | 2015 | 6 | 0.140 |
Why?
|
| Sexual Behavior | 6 | 2017 | 587 | 0.140 |
Why?
|
| Nitriles | 2 | 2016 | 66 | 0.140 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2006 | 41 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 468 | 0.140 |
Why?
|
| Pyrimidines | 2 | 2016 | 112 | 0.130 |
Why?
|
| Social Justice | 2 | 2018 | 53 | 0.130 |
Why?
|
| Administration, Rectal | 3 | 2019 | 17 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 195 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2018 | 1961 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2017 | 219 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 1426 | 0.120 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 2 | 0.120 |
Why?
|
| Cyclopropanes | 3 | 2020 | 39 | 0.120 |
Why?
|
| Alkynes | 3 | 2020 | 49 | 0.120 |
Why?
|
| Culture | 2 | 2013 | 162 | 0.120 |
Why?
|
| Patient Compliance | 2 | 2005 | 202 | 0.120 |
Why?
|
| Occupational Diseases | 1 | 2013 | 45 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2013 | 97 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2015 | 392 | 0.110 |
Why?
|
| Pyridines | 1 | 2013 | 113 | 0.110 |
Why?
|
| Caribbean Region | 1 | 2012 | 63 | 0.110 |
Why?
|
| Patient Selection | 1 | 2013 | 154 | 0.110 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2016 | 10 | 0.110 |
Why?
|
| Down Syndrome | 1 | 2011 | 29 | 0.100 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 1003 | 0.100 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2011 | 33 | 0.100 |
Why?
|
| Area Under Curve | 3 | 2015 | 91 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 423 | 0.100 |
Why?
|
| Delivery, Obstetric | 3 | 2006 | 38 | 0.100 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 44 | 0.100 |
Why?
|
| United States | 4 | 2009 | 3894 | 0.100 |
Why?
|
| Perinatal Care | 2 | 2008 | 15 | 0.100 |
Why?
|
| Contraceptive Devices, Female | 2 | 2020 | 2 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2010 | 75 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2015 | 541 | 0.090 |
Why?
|
| Risk Factors | 6 | 2012 | 3414 | 0.090 |
Why?
|
| Drug Interactions | 2 | 2020 | 137 | 0.090 |
Why?
|
| Genotype | 3 | 2020 | 641 | 0.090 |
Why?
|
| Models, Educational | 1 | 2009 | 41 | 0.090 |
Why?
|
| Psychometrics | 1 | 2010 | 292 | 0.080 |
Why?
|
| Immunity, Cellular | 2 | 2008 | 68 | 0.080 |
Why?
|
| Herpes Genitalis | 1 | 2008 | 6 | 0.080 |
Why?
|
| Herpesvirus 2, Human | 1 | 2008 | 9 | 0.080 |
Why?
|
| Homosexuality, Male | 3 | 2019 | 438 | 0.080 |
Why?
|
| Drug Administration Schedule | 3 | 2016 | 145 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2012 | 371 | 0.080 |
Why?
|
| Lamivudine | 1 | 2007 | 20 | 0.080 |
Why?
|
| Postpartum Period | 2 | 2015 | 59 | 0.080 |
Why?
|
| Cultural Competency | 1 | 2009 | 120 | 0.080 |
Why?
|
| Drug Resistance, Viral | 3 | 2010 | 60 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 205 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2017 | 212 | 0.080 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2007 | 203 | 0.070 |
Why?
|
| Puerperal Disorders | 1 | 2006 | 6 | 0.070 |
Why?
|
| Prenatal Care | 1 | 2007 | 74 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2007 | 316 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 446 | 0.070 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2008 | 165 | 0.070 |
Why?
|
| Schools, Medical | 1 | 2007 | 192 | 0.070 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 47 | 0.070 |
Why?
|
| Papillomaviridae | 1 | 2006 | 125 | 0.070 |
Why?
|
| Medication Adherence | 2 | 2017 | 165 | 0.070 |
Why?
|
| Mothers | 1 | 2007 | 164 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 181 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2006 | 233 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2015 | 235 | 0.060 |
Why?
|
| Fetal Weight | 1 | 2023 | 9 | 0.060 |
Why?
|
| Vagina | 2 | 2020 | 81 | 0.060 |
Why?
|
| Fetal Development | 1 | 2023 | 29 | 0.060 |
Why?
|
| Women's Health | 1 | 2004 | 135 | 0.060 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2013 | 8 | 0.060 |
Why?
|
| Zidovudine | 1 | 2003 | 33 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2013 | 53 | 0.060 |
Why?
|
| Mass Screening | 1 | 2007 | 427 | 0.060 |
Why?
|
| Genitalia, Female | 1 | 2003 | 26 | 0.060 |
Why?
|
| Adenoviridae Infections | 1 | 2012 | 4 | 0.050 |
Why?
|
| Circumcision, Male | 1 | 2012 | 7 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2012 | 59 | 0.050 |
Why?
|
| Sexual Partners | 2 | 2017 | 308 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 316 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2012 | 72 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2012 | 154 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2005 | 469 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2008 | 517 | 0.050 |
Why?
|
| Time Factors | 2 | 2012 | 1681 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 48 | 0.050 |
Why?
|
| Ethinyl Estradiol | 1 | 2020 | 9 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 45 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 102 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 343 | 0.040 |
Why?
|
| Reproductive Rights | 1 | 2018 | 2 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2020 | 165 | 0.040 |
Why?
|
| DNA, Viral | 3 | 2006 | 295 | 0.040 |
Why?
|
| Progesterone | 1 | 2019 | 117 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 30 | 0.040 |
Why?
|
| Transaminases | 1 | 2008 | 7 | 0.040 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2008 | 5 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 254 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2013 | 1318 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2008 | 65 | 0.040 |
Why?
|
| Hepatitis B | 1 | 2008 | 39 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2008 | 59 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2004 | 322 | 0.040 |
Why?
|
| Lubricants | 1 | 2017 | 4 | 0.040 |
Why?
|
| Disease Progression | 3 | 2006 | 580 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 233 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2018 | 136 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 155 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2008 | 120 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 102 | 0.040 |
Why?
|
| Glycerol | 1 | 2017 | 29 | 0.040 |
Why?
|
| Aged | 2 | 2008 | 6448 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2008 | 298 | 0.040 |
Why?
|
| Mutation | 2 | 2011 | 1023 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 638 | 0.040 |
Why?
|
| Child | 1 | 2013 | 2875 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2006 | 429 | 0.030 |
Why?
|
| Infant, Premature | 2 | 2005 | 128 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 2013 | 11 | 0.030 |
Why?
|
| Dominican Republic | 1 | 2013 | 20 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 375 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 17 | 0.030 |
Why?
|
| Plasma | 1 | 2013 | 29 | 0.030 |
Why?
|
| Haiti | 1 | 2013 | 59 | 0.030 |
Why?
|
| Informed Consent | 1 | 2013 | 30 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 25 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2005 | 570 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 256 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2008 | 841 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2008 | 1056 | 0.030 |
Why?
|
| Pregnancy Trimesters | 1 | 2011 | 15 | 0.030 |
Why?
|
| Prevalence | 2 | 2006 | 1425 | 0.030 |
Why?
|
| Nucleotides | 1 | 2011 | 33 | 0.030 |
Why?
|
| Adenine | 1 | 2011 | 43 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2011 | 21 | 0.030 |
Why?
|
| Nucleosides | 1 | 2011 | 27 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2013 | 435 | 0.020 |
Why?
|
| Smoking | 2 | 2006 | 903 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 22 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2007 | 27 | 0.020 |
Why?
|
| Creatinine | 1 | 2007 | 101 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 859 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2006 | 7 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 121 | 0.020 |
Why?
|
| Triplets | 1 | 2005 | 4 | 0.020 |
Why?
|
| Twins | 1 | 2005 | 16 | 0.020 |
Why?
|
| Comorbidity | 1 | 2008 | 606 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2005 | 53 | 0.020 |
Why?
|
| Memory | 1 | 2006 | 165 | 0.020 |
Why?
|
| Parturition | 1 | 2005 | 22 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2008 | 727 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2005 | 42 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2004 | 151 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2004 | 39 | 0.020 |
Why?
|
| Gestational Age | 1 | 2005 | 190 | 0.020 |
Why?
|
| Half-Life | 1 | 2004 | 52 | 0.020 |
Why?
|
| Labor, Obstetric | 1 | 2004 | 15 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2004 | 89 | 0.020 |
Why?
|
| Gravidity | 1 | 2003 | 3 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 528 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2004 | 123 | 0.010 |
Why?
|
| Virus Shedding | 1 | 2003 | 9 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2003 | 43 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 1007 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 882 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 964 | 0.010 |
Why?
|